Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: A report from the BINGO study

Cancer Science

Volumn 101, Issue 10, 2010, Pages 2186-2192

  Ishikawa, Yuichi ^a   Kiyoi, Hitoshi ^a   Watanabe, Keisuke ^b   Miyamura, Koichi ^b   Nakano, Yasuyuki ^c   Kitamura, Kunio ^d   Kohno, Akio ^e   Sugiura, Isamu ^f   Yokozawa, Toshiya ^g   Hanamura, Akitoshi ^h   Yamamoto, Kazuhito ⁱ   Iida, Hiroatsu ^j   Emi, Nobuhiko ^k   Suzuki, Ritsuro ^l   Ohnishi, Kazunori ^m   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c Yokkaichi Municipal Hospital   (Japan)

^d Ichinomiya Municipal Hospital   (Japan)

^e Aichi Prefectural Welfare Federation of Agriculture Co operative Associations Konan Kosei Hospital   (Japan)

^f TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^h GIFU PREFECTURAL TAJIMI HOSPITAL   (Japan)

ⁱ AICHI CANCER CENTER HOSPITAL   (Japan)

^j Meitetsu Hospital   (Japan)

^k FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; OROSOMUCOID; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; ENZYME INHIBITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; BLOOD; LEUKEMIA, MYELOID, CHRONIC-PHASE; MEDICATION COMPLIANCE; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OROSOMUCOID; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 77957056455     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01643.x     Document Type: Article

References (32)

1. Druker BJ, Talpaz M, Resta DJ. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-7.
2. O'Brien SG, Guilhot F, Larson RA. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
3. Druker BJ, Guilhot F, O'Brien SG. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-17.
4. Baccarani M, Saglio G, Goldman J. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-20.
5. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007, 110:2828-37.
6. Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007, 8:1116-28.
7. Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 2008, 93:161-9.
8. Jabbour E, Hochhaus A, Cortes J, La Rosee P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 2010, 24:6-12.
9. Gorre ME, Mohammed M, Ellwood K. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-80.
10. Radich JP, Dai H, Mao M. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006, 103:2794-9.
11. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007, 8:1018-29.
12. Peng B, Hayes M, Resta D. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004, 22:935-42.
13. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005, 44:879-94.
14. Larson RA, Druker BJ, Guilhot F. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-8.
15. Picard S, Titier K, Etienne G. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-9.
16. Sakai M, Miyazaki Y, Matsuo E. Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. Int J Hematol 2009, 89:319-25.
17. Jorgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD. Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 2002, 99:713-15.
18. Gambacorti-Passerini C, Barni R, le Coutre P. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000, 92:1641-50.
19. Gambacorti-Passerini C, Zucchetti M, Russo D. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003, 9:625-32.
20. Levis M, Brown P, Smith BD. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006, 108:3477-83.
21. Osumi K, Fukui T, Kiyoi H. Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR. Leuk Lymphoma 2002, 43:2291-9.
22. Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 768:325-40.
23. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009, 23:1537-44.
24. O'Brien SG, Meinhardt P, Bond E. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003, 89:1855-9.
25. Bolton AE, Peng B, Hubert M. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004, 53:102-6.
26. Dutreix C, Peng B, Mehring G. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004, 54:290-4.
27. Beumer JH, Natale JJ, Lagattuta TF, Raptis A, Egorin MJ. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. Pharmacotherapy 2006, 26:903-7.
28. de Lavallade H, Apperley JF, Khorashad JS. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26:3358-63.
29. Baccarani M, Cortes J, Pane F. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-51.
30. Hughes TP, Kaeda J, Branford S. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-32.
31. Hughes T, Hochhaus A, Branford S. Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: an Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP). Blood 2008, 112:129-30.
32. Hughes TP, Branford S, White DL. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008, 112:3965-73.